Hydroxychloroquine

The FDA has approved an abbreviated new drug application for hydroxychloroquine sulfate tablets to address ongoing shortages of the drug sparked by its still unproven potential as a COVID-19 treatment.

As the enormity of the COVID-19 pandemic sinks in and as we feel its impact across the globe, join us as we discuss mitigation, solutions and new discoveries and approaches to help you better prepare to serve your patients across all specialties. In this episode, we focus on immunocompromised patients.

The American Thoracic Society has released new guidance on how to approach treatment of COVID-19 during the global pandemic.

Recent reports have lauded hydroxychloroquine and chloroquine — drugs previously approved to treat malaria and rheumatic conditions — as a potential treatment for COVID-19.

Rheumatologists, rheumatology patients and the organizations who represent both have reacted this week with a mixture of hope and dread following the FDA’s decision allowing the emergency use of hydroxychloroquine to treat some patients hospitalized with COVID-19.

More than 50 rheumatology societies, including the American College of Rheumatology, have urged U.S. governors to ensure judicious use of hydroxychloroquine and chloroquine for investigational COVID-19 purposes, given that these drugs are essential for many rheumatology patients.

An international group of more than a dozen rheumatologists have cosigned an article published in Annals of Internal Medicine discouraging the off-label use of hydroxychloroquine for COVID-19, until said use is justified by data and the drug’s supply is replenished.

In the wake of increasing reports of hydroxychloroquine shortages in the United States, sparked by its still-untested potential as a COVID-19 treatment, the American College of Rheumatology has issued new guidelines on its scarce allocation.

The American College of Rheumatology, the Lupus Foundation of America, the Arthritis Foundation and the American Academy of Dermatology have issued a joint statement calling on Vice President Mike Pence to address shortages of hydroxychloroquine and chloroquine, following comments from White House regarding their potential use in treating COVID-19.

Late last week, President Donald Trump sent shockwaves through the medical industry when he announced in a press conference that the FDA had approved the anti-malarial hydroxychloroquine to treat patients infected with coronavirus.